Overview |
bs-11321R |
Islet 2 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Human, Mouse, Rat, Dog, Cow, Sheep, Horse, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human Islet 2 |
201-300/359 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
Nucleus |
Insulin gene enhancer protein ISL 2; Insulin gene enhancer protein ISL-2; Insulin gene enhancer protein ISL2; ISL 2; ISL 2 transcription factor; ISL 2 transcription factor LIM/homeodomain; ISL2; ISL2 transcription factor; ISL2 transcription factor LIM/homeodomain; ISL2_HUMAN; Islet-2; Islet2; FLJ10160. |
Islet-2 (insulin gene enhancer protein ISL-2) is a 359 amino acid protein encoded by the human gene ISL2. Islet-2 is a nuclear protein that contains two N-terminal LIM domains, followed by a homeodomain and a serine/ glutamine/threonine-rich C-terminus. Islet-2 is a transcriptional factor that defines subclasses of motor neurons that segregate into columns in the spinal cord and select distinct axon pathways. Islet-1 and Islet-2 are initially ex-pressed by all postmitotic spinal motor neurons prior to diversification of somatic and visceral neuronal fates. Somatic, but not visceral, motor neurons maintain Islet-2 expression at later embryonic stages. An early phase of Islet-2 expression by prospective visceral motor neurons of the sympathetic preganglionic motor column is critical for the emergence of complete visceral motor neuron character. Mutations that reduce or eliminate both Islet-1 and Islet-2 activity will result in pronounced defects in visceral motor neuron generation and eroded somatic motor neuron character. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |